EGFR and colorectal carcinoma: Thus, by next investigating the current predictive marker RAS mutation status by targeted next generation sequencing (tNGS), we identified RAS mutations in CRC cell lines and tissue specimens of CRC patients treated by EGFR-targeted therapy.